Theravance Biopharma (TBPH) Return on Capital Employed (2014 - 2026)

Theravance Biopharma (TBPH) has 13 years of Return on Capital Employed data on file, last reported at 0.3% in Q1 2026.

• On a quarterly basis, Return on Capital Employed rose 1611.0% year-over-year to 0.3% in Q1 2026; TTM through Mar 2026 was 0.3%, a 1611.0% increase from a year earlier, with the FY2025 full-year figure at 0.94%, up 1303.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 0.3%, up from 0.87% in the prior quarter.
• Over the last five years, Return on Capital Employed for TBPH reached as high as 0.3% in Q1 2026 and fell as low as 66.19% in Q1 2022.
• Historically, Return on Capital Employed has averaged 18.44% across 5 years, with a median of 14.33% in 2023.
• Across the five-year window, Return on Capital Employed jumped 6403 bps in 2022 and sank 389 bps in 2025, its largest moves.
• Year by year, Return on Capital Employed stood at 14.0% in 2022, then slipped by 7 bps to 15.02% in 2023, then advanced by 3 bps to 14.53% in 2024, then surged by 94 bps to 0.87% in 2025, then jumped by 135 bps to 0.3% in 2026.
• Per Business Quant data, the three most recent Return on Capital Employed figures were 0.3% in Q1 2026, 0.87% in Q4 2025, and 8.56% in Q3 2025.